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To our knowledge, very few data about the role of Topoisomerase IIa (TOPO-IIa), an enzyme involved in critical steps of tumour cell
proliferation and chemoresistance are currently available in ovarian cancer patients. The aim of this study was to investigate the
prognostic value of TOPO-IIa expression in a large, single institution series of 96 primary untreated advanced ovarian cancer patients
admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome. Immunohistochemistry was carried out
by using the MoAb anti-human TOPO-IIa antibody (clone Ki-S1). TOPO-IIa immunoreaction was observed in 70 out of 96 cases
(72.9%), and the percentages of positively stained cells ranged between 1 and 83% (median¼10%). There was no association with
clinico-pathological parameters. During the follow up period, progression and death of disease were observed in 76 (79.2%) and 45
(46.9%) cases. A statistically significant direct association between the percentages of positively immunostained tumour cells and the
relative risk of death was observed (w
2¼6.6, P-value¼0.0101). In multivariate analysis, only platinum resistance, advanced stage of
disease and high levels of TOPO-IIa expression retained an independent negative prognostic role for OS. The unfavourable role of
high TOPO-IIa expression was maintained only in the subgroup of platinum resistant recurrent ovarian cancer patients, be TOPO-IIa
expression evaluated as continuous variable (w
2¼5.1, P-value¼0.024), or by means of the defined cutoff point. Our study suggests
that the assessment of TOPO-IIa could be helpful to identify poor prognosis platinum-resistant ovarian cancer patients, potentially
candidates to investigational agents.
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Despite the advances in surgical efforts, and the achievement of
high response rates with platinum/paclitaxel front-line treatment
(McGuire et al, 1996; Eisenkop et al, 2003; Ozols et al, 2003),
ovarian cancer remains the most lethal gynaecological malignancy
with a 5-year survival rate of 25–30% in advanced stage disease
(Jemal et al, 2007). The major determinants of clinical outcome are
represented by the extent of residual tumour at primary surgery,
and sensitivity to platinum-based chemotherapy (Armstrong,
2007): Indeed, in platinum-resistant ovarian cancer patients,
salvage chemotherapy with non-platinum agents mostly results
in short-lived response rates, and poor survival (Armstrong, 2007).
In this context, efforts aimed at identifying molecular factors
eventually involved in chemotherapy resistance are actively
ongoing. Several observations have recently suggested that
Topoisomerase IIa (TOPO-IIa), one of the two isoforms an
enzyme playing a relevant role in DNA replication, repair, and
transcription (Chung et al, 1989), is involved in critical steps of
tumour cell proliferation and chemoresistance (Wang, 2002).
Strong TOPO-IIa expression or enzymatic activity have been
documented in ovarian carcinoma compared to the hardly
detectable levels in benign ovarian tumours, ovarian inclusion
cysts, and normal surface epithelium (van der Zee et al, 1991;
Cornarotti et al, 1996; Withoff et al, 1999; Chekerov et al, 2006).
The frequency of TOPO-IIa overexpression in ovarian cancer has
been reported to range between 30 and 70% (van der Zee et al,
1994; Gotlieb et al, 2001; Koshiyama et al, 2001), and a definite role
of this enzyme as a marker of sensitivity not only to TOPO-IIa
targeting agents, such as anthracyclines and etoposide, but also to
platinum agents in vitro and in vivo has been documented
(Kikuchi et al, 1997; Naniwa et al, 2007).
In particular, a significant correlation between elevated
TOPO-IIa expression and tumour sensitivity to cisplatin-based
chemotherapy has been shown in 37 primary untreated ovarian
carcinomas (Cornarotti et al, 1996). While these observations
favour the possibility that TOPO-IIa overexpression could identify
ovarian cancer patients with better clinical outcome, on the other
hand other authors suggested that it might serve as a marker of
aggressive features and poor prognosis (Gotlieb et al, 2001;
Brustmann 2004; Mano et al, 2004). The discrepancies across
earlier studies might be explained by the different design, the
methodologies of TOPO-IIa assessment, the small sample series,
and the lack of data on salvage treatment (Cornarotti et al, 1996;
Gotlieb et al, 2001; Brustmann 2004; Mano et al, 2004): indeed, it
has to be taken into account that the analysis of the potential
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sprognostic impact of TOPO-IIa might be someway influenced by
the role played by the same target as predictor of sensitivity to
TOPO-IIa inhibitory drugs, often used in the salvage setting.
To our knowledge, very few data about the role of TOPO-IIa
expression in predicting clinical outcome of ovarian cancer
patients is currently available (Gotlieb et al, 2001; Brustmann
2004).
The aim of this study was to investigate the prognostic value of
immunohistochemically assessed TOPO-IIa expression in a large,
single institution series of primary untreated advanced ovarian
cancer patients.
PATIENTS AND METHODS
Patients
The study included 96 ovarian cancer patients admitted to the
Gynecologic Oncology Unit, Catholic University of Campobasso
and Rome. In our Institution a written informed consent is
routinely requested to patients for collection of their clinical data,
as well as paraffin embedded sections for research use. Clinico-
pathological characteristics of the overall series are summarised in
Table 1.
Median age was 60 years (range, 27–80). Seventy-seven cases
(80.2%) were stage III and 19 (19.8%) cases were stage IV disease.
According to the standard guidelines, maximal surgical effort has
been attempted in all patients resulting in optimal debulking
(residual tumouro1cm) in 41 (42.7%) cases, which underwent
surgical removal of tumour masses, along with total abdominal
hysterectomy, adnexectomy, radical omentectomy appendectomy,
multiple biopsies, and additional surgery (intestinal resections,
diaphragm stripping) when required. Radical pelvic and para-
aortic lymphadenectomy was performed in all patients undergoing
primary cytoreduction who had residual tumour o1cm. Sub-
optimal cytoreduction (residual tumour 41cm) was achieved in
15 (15.6%) cases. Forty cases (41.7%) were judged to be
unresectable at first surgery because of extensive peritoneal bulky
carcinomatosis, agglutinated bowel/mesentery and infiltration of
the upper gastrointestinal tract and /or the major vessels, and were
submitted only to multiple biopsies. All patients received
platinum-based chemotherapy (75–100mgm
 2 for cisplatin,
AUC¼5 for carboplatin, per cycle), including also paclitaxel
(135–175mgm
 2 for each cycle) in 91 (94.8%) of cases. As far as
patients undergoing only exploratory laparotomy are concerned,
they received 3–4 cycles of chemotherapy before attempting a
second cytoreductive surgery, unless they showed clinical progres-
sion during treatment. Response to chemotherapy was assessed
according to WHO criteria (World Health Organization, 1979).
In the subgroup of patients who were not susceptible to be
cytoreduced at first surgery, a direct assessment of the extent of
response to chemotherapy was carried out at time of second
laparotomy. At recurrence/progression of disease platinum
sensitive patients were triaged to platinum/taxane-containing
regimen, while platinum-resistant patients were administered
pegylated liposomal doxorubicin (PLD) according to clinical trials
ongoing in our Institution (Ferrandina et al, 2007, 2008).
Immunohistochemistry
Pretreatment tumour tissues biopsies were obtained at first
surgery in all cases. Tissue specimens were fixed in 10% formalin
and paraffin-embedded according to standard procedures. Immuno-
staining was performed on 3mm tissue sections mounted on
poly-l-lysine-coated slides and dried at 371C overnight. After the
slides were deparaffinised in xylene, and rehydrated convention-
ally, the endogenous peroxidase activity was blocked with 3% H2O2
in TBS for 5min. Antigen retrieval procedure was performed by
microwave oven heating in citrate buffer (pH¼6). Sections were
incubated with 20% normal goat serum for 30min at room
temperature to reduce nonspecific binding, then with the
monoclonal mouse anti-human TOPO-IIa antibody (clone Ki-S1)
(diluted 1:50) (Dako Cytomation, Denmark) in 20% goat serum.
TOPO-IIa detection was evaluated by a labelled polymer The En
Vision-mouse þ System-HRP System (DAKO, Carpinteria, CA,
USA) was used. Diaminobenzidine was used as a chromogen
(DAB substrate System, DAKO). Positive controls for TOPO-IIa
was represented by sections taken from the breast. Results were
expressed as the proportion of immunostained tumour cells.
The analysis of all tissue sections was done without any prior
knowledge of the clinical parameters by two authors (AC, GFZ) by
means of light microscopy. The proportion of immunostained
tumour cells was scored at low magnification ( 5 objective lens)
by evaluating the entire tumour area. The accuracy of immuno-
histochemical readings was evaluated by assessing intra-and
inter-observer variability (mean±s.d.¼8%±2, and 12%±3,
respectively).
Statistical analysis
Wilcoxon signed ran sum test was used to analyse the expression
levels of TOPO-IIa according to clinico-pathological parameters.
Time to progression and overall survival (OS) were calculated from
Table 1 Clinico-pathological characteristics of the overall series, and
TOPO-IIa expression
Percentage of
TOPO-IIa positive
cells
Characteristics
No. of patients
(%) Median (range) P-value
a
All cases 96 5 (0–83)
Age (years)
p65 31 (32.3) 4 (0–50)
465 65 (67.7) 5 (0–83) 0.4
FIGO Stage
III 77 (80.2) 5 (0–83)
IV 19 (19.8) 3 (0–50) 0.5
Grade
G1-2 18 (18.7) 5 (0–60)
G3 67 (69.8) 5 (0–83) 0.8
n.a. 11
Histotype
Serous 84 (87.5) 5 (0–83)
Other 12 (12.5) 4 (0–50) 0.6
Residual tumour
o1cm 41 (42.7) 4 (0–60)
41cm 15 (15.6) 4 (0–40)
Exploratory
laparotomy
40 (41.7) 7 (0–83) 0.7
b
Primary chemotherapy
Platinum/paclitaxel 91 (94.8) 5 (0–83)
Platinum-based 5 (5.2) 5 (0–18) 0.8
Response to CT
Yes 48 (50.0) 4.5 (0–60)
No 48 (50.0) 5 (0–83) 0.8
n.a.¼not available.
aCalculated by Mann–Whitney nonparametric test.
bCalculated
by Kruskall–Wallis sum test.
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sthe date of diagnosis to the date of progression/death or date
last seen. Medians and life tables were computed using the
product-limit estimate by the Kaplan and Meyer (1958) method
and the log–rank test was employed to assess the statistical
significance (Mantel, 1966). Statistical analysis was carried
out using SOLO (BMDP Statistical Software, Los Angeles,
CA, USA). Multivariate analysis assessing the clinical role of
TOPO-IIa expression matched with other clinico-pathological
characteristics was performed by Cox’s proportional hazards
model (Cox, 1972).
RESULTS
Figure 1 shows representative examples of high vs low TOPO-IIa
expression in primary ovarian cancer. Specific immunostaining for
TOPO-IIa was exclusively confined to the nuclei, and showed a
wide range of variability: in the overall series, TOPO-IIa
immunoreaction was observed in 70 out of 96 cases (72.9%), and
the percentages of positively stained cells ranged between 1 and
83% (median¼10%). Given the large inter-tumour variability, the
absence of a defined scoring system, and the need to minimise any
source of bias related to the use of a specific cutoff value, analysis
of the data was carried out by using the values of TOPO-IIa as a
continuous variable.
The percentages of TOPO-IIa immunoreactive tumour cells were
found not to be associated with any of the clinico-pathological
parameters examined. Moreover, no association with response to
first-line treatment was documented (Table 1).
Follow-up data were available for all patients. As of December
2007, the median follow up was 37 months (range, 6–120). During
the follow up period, progression and death of disease were
observed in 76 (79.2%) and 45 (46.9%) cases.
Figure 2 shows the plot of the estimates of the relative risk of
progression or death as a prediction of TOPO-IIa values,
calculated by COX’s proportional hazard regression model: there
was no association between the percentage values of positively
TOPO-IIa immunostained tumour cells and the relative risk of
progression of disease (w
2¼2.3, P-value¼0.12).
On the other hand, a statistically significant direct association
between the percentages of TOPO-IIa positively immunostained
tumour cells and the relative risk of death was observed (w
2¼6.6,
P-value¼0.0101) (see also Table 2).
We were then prompted at defining the cutoff value of TOPO-IIa
that more closely correlated with the risk of death: the most
significant association was observed at the cutoff value of 25%
TOPO-IIa immunoreactive cells: cases with high TOPO-IIa
expression has a shorter OS (median OS¼35 months) than cases
with low TOPO-IIa levels (median¼54 months) (P-value¼0.048)
(Figure 3).
In univariate analysis of OS, platinum resistance, more advanced
stage of disease, and suboptimal residual tumour at primary
surgery were also found to be associated with a high risk of death
of disease (Table 2). In multivariate analysis, only platinum
resistance, more advanced stage of disease and high levels of
TOPO-IIa expression retained an independent negative prognostic
role for OS (Table 2).
We were then prompted at analyzing the prognostic relevance of
TOPO-IIa expression in platinum-sensitive vs platinum-resistant
ovarian cancer patients: interestingly enough, the unfavourable
role of high TOPO-IIa expression was maintained only in the
subgroup of platinum-resistant recurrent ovarian cancer patients,
be it evaluated as continuous variable (w
2¼5.1, P-value¼0.024),
or by means of the defined cutoff point: cases with high TOPO-IIa
expression has a shorter OS (median OS¼18 months) than cases
with low TOPO-IIa levels (median¼35 months) (P-value¼0.041)
(data not shown).
DISCUSSION
This is the first study analysing the association between the
expression of TOPO-IIa protein and clinical outcome in a large
series of primary untreated ovarian cancer patients.
A
C
B
D
Figure 1 TOPO-IIa immunoreaction in primary ovarian cancer. (A) Positive control (human breast cancer tissue specimen), (B) negative control (ovarian
carcinoma) for TOPO-IIa staining. Representative examples of high (C) and low (D) TOPO-IIa expression. (A, B, C, D) Magnification¼ 200.
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of TOPO-IIa experience a shorter OS compared to cases with low
TOPO-IIa content, as also suggested by preliminary studies
(Gotlieb et al, 2001; Mano et al, 2004).
The analysis of the percentages of positively TOPO-IIa
immunostained cells as a continuous value allowed to avoid the
potential bias inherent in the use of an arbitrary cutoff point, and
further supported the association of high TOPO-IIa expression
with a high risk of death of disease.
The independent role of high TOPO-IIa expression as marker of
poor prognosis is sustained by the lack of association with any of
the clinico-pathological parameters examined, and also by the
results of multivariate analysis documenting the persistence of
the unfavourable significance of high TOPO-IIa expression after
adjusting for stage of disease, residual tumour, and platinum
responsiveness.
The association between TOPO-IIa overexpression and poor
prognosis has been reported in other human tumours, including
breast and bladder carcinomas (Kruger et al, 2005; O’Connor et al,
2006) as well as glioblastoma and lymphoma (Ho et al, 2003;
Schrader et al, 2004); however, the assessment of whether the
prognostic impact of this parameter is due to its value as predictor
of response to treatment-based regimen or as a marker of intrinsic
tumour aggressiveness (pure prognostic factor), is difficult to be
established. Indeed, the data about the role of TOPO-IIa in
determining susceptibility to platinum agents are very controver-
sial since increased levels of TOPO-IIa have been found both in cell
lines or small subsets of patients resistant to alkylating agents or
platinum drugs (de Jong et al, 1990; Chu, 1994; Kikuchi et al,
1997), as well as in in vitro models and ovarian cancer patients
exhibiting sensitivity to cisplatin (Giaccone et al, 1992; Cornarotti
et al, 1996; Koshiyama et al, 2001). In our series, we could not
detect any difference in the distribution of TOPO-IIa values
according to response to first line chemotherapy, or time to
progression, the latter one being strictly associated with treatment
susceptibility, thus suggesting that overexpression of TOPO-IIa
might more likely indicate tumour-intrinsic biological aggressive-
ness, rather than represent only a marker of platinum sensitivity.
In this context, it is noteworthy that TOPO-IIa is involved in
several biological pathways of tumour aggressiveness: for instance,
TOPO-IIa is correlated with the proliferation associated marker
ki67 (Costa et al, 2000), the Vascular Endothelial Growth Factor
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Figure 2 Plot of the estimates of the relative risk of progression (A) and
death (B) of disease as a prediction of TOPO-IIa values, calculated by
COX’s proportional hazard regression model.
Table 2 Univariate and multivariate analysis of clinico-pathological
parameters and TOPO-IIa as prognostic factors for overall survival in
advanced ovarian cancer patients
Univariate Multivariate
a
Variable RR1 v
2 P-value RR2 v
2 P-value
Age (years)
o65 1
0 —— —
465 1.2 0.3 0.6
Stage
III 1
0 1
0
IV 3.0 9.4 0.0021 1.96 7.1 0.008
Extent of residual tumour
o1cm 1
0 1
0
41cm 3.1 9.5 0.0020 1.63 1.5 0.22
Response to treatment
No 1
0 1
0
Yes 9.7 35.0 0.0001 8.2 30.2 0.0001
Topo-IIa percentages
1
0 1
0
Continuous data
b 1.02
b 6.6 0.0101 1.02
b 3.9 0.0477
1
0¼Reference category. w
2 of the model¼45.7; P-value¼0.0001.
aOnly variables
with P-valueo0.20 in the univariate analysis were included in the multivariate model,
RR1¼unadjusted relative risk, RR2¼relative risk after adjusting for all the factors
listed
bRelative risk per percentage unit of Topo-IIa increase.
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Figure 3 Overall survival curves in ovarian cancer patients according to
the status of TOPO-IIa.
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oncogene (Mano et al, 2004; Hicks et al, 2005); moreover, TOPO-IIa
expression seems to be regulated by p53 oncosuppressor gene
(Sandri et al, 1996), whose mutations are differentially involved in
platinum vs paclitaxel sensitivity in ovarian cancer (Ferrandina
et al, 1999; Lavarino et al, 2000). Interestingly enough, the
unfavourable prognostic role of high TOPO-IIa content was
documented only in the subgroup of platinum-resistant ovarian
cancer patients. This finding, which cannot be ascribed to
differences in the expression levels of TOPO-IIa according to
platinum sensitivity, raises some issues: (i) the availability of a
molecular factor able to discriminate high- vs low-risk patients in
the platinum-resistant subgroup seems clinically relevant, when
considering that the prognosis of patients defined as platinum-
resistant is so unfavourable, that any other factor is expected to
become minor, if any, importance in terms of prognostic
discrimination; (ii) considering that in our series all platinum-
resistant recurrent ovarian cancer patients were administered
doxorubicin, our findings seem to demonstrate that the role of
TOPO-IIa as an unfavourable prognostic factor might overcome its
role as a predictor of response to TOPO-IIa-targeting agents: the
discrepancy with in vitro data (Koshiyama et al, 2001) has to be
considered in the light of the common experience that tissue
specimens represent a different picture from ‘in vitro’ models: the
contribution of inflammatory and endothelial cells in the stroma,
is likely to realise a regulatory microenvironment which might
somehow hide the straight biochemical relationships found in cell
cultures. In this context, recent observations have been provided
(Chekerov et al, 2006) that the pattern of expression of TOPO-IIa
in ovarian cancer varies in epithelial vs adjacent stromal cell
component. It remains to be clarified why TOPO-IIa expression
has definitely a strong clinical impact only in the subgroup of
platinum-resistant ovarian cancer patients: it is conceivable that a
specific molecular profile might characterise platinum-resistant
ovarian carcinomas compared to platinum-sensitive ones,
so that only in this subset of patients TOPO-IIa might be
coexpressed with molecular factor(s) eventually involved in
determining more aggressive tumour features. These observations
emphasize the need to proceed to a multiparametric evaluation
of several biologically linked molecular targets, to possibly
define clusters of patients with a more aggressive tumour
‘molecular profile’.
In conclusion, although these findings need to be confirmed in a
larger series, our study suggests that the assessment of TOPO-IIa
could be helpful to identify poor prognosis platinum resistant
ovarian cancer patients, potentially candidates to investigational
agents.
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